139 results
8-K
EX-99.1
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E
8-K
EX-99.2
RVNC
Revance Therapeutics Inc
9 May 24
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update
4:08pm
in China with our partner, Shanghai Fosun Pharmaceutical; constitute forward-looking statements within the meaning of the Private Securities Litigation
8-K
EX-1.1
RVNC
Revance Therapeutics Inc
5 Mar 24
Other Events
5:08pm
annual or interim period during the current or prior three fiscal years; or (iii) any Internal Control Event.
(cc) Litigation. Except as disclosed … , in case of any notice pursuant to Section 9(c) hereof, to the Director of Litigation, Office of the General Counsel, Barclays Capital Inc., 745 Seventh
424B5
5bntdu
5 Mar 24
Prospectus supplement for primary offering
5:00pm
424B5
htppzpis ofvw5trdun
4 Mar 24
Prospectus supplement for primary offering
6:39am
8-K
EX-10.2
n3i1ai7
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-99.1
kp5d8l47ly0q0
28 Feb 24
Provides Corporate Update
4:07pm
8-K
EX-10.1
lscw2
13 Feb 24
Departure of Directors or Certain Officers
4:28pm
8-K
EX-99.1
sia40o1
8 Jan 24
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
8:01am
8-K
EX-99.1
3cb8pm
8 Nov 23
Provides Corporate Update
4:09pm
8-K
EX-99.1
tn23o y1um22q0y1
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.2
uafs90nvpe88p cfa
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
k1js1 ggx1
19 Sep 23
Revance Provides Corporate Update at Investor Day
9:01am
8-K
EX-99.1
kzak4 3z165l0
8 Aug 23
Provides Corporate Update
4:08pm